David Colleran - 14 Mar 2025 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Signature
/s/ David Colleran
Issuer symbol
ANIK
Transactions as of
14 Mar 2025
Net transactions value
-$30,118
Form type
4
Filing time
18 Mar 2025, 17:16:12 UTC
Previous filing
13 Mar 2025
Next filing
11 Mar 2026

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIK Common Stock Options Exercise $0 +6,448 +15% $0.000000 49,847 17 Mar 2025 Direct F1
transaction ANIK Common Stock Tax liability $30,118 -1,893 -3.8% $15.91 47,954 17 Mar 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Award $0 +28,165 $0.000000 28,165 14 Mar 2025 Common Stock 28,165 $0.000000 Direct F4
transaction ANIK Restricted Stock Unit Award $0 +13,669 $0.000000 13,669 14 Mar 2025 Common Stock 13,669 $0.000000 Direct F5
transaction ANIK Restricted Stock Unit Options Exercise $0 -6,448 -33% $0.000000 12,897 17 Mar 2025 Common Stock 6,448 $0.000000 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the first vesting installment of RSUs granted on March 15, 2024, which the Company elected to settle in shares.
F2 Reflects an aggregate of 1,893 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2025.
F3 Reflects the closing price of ANIK common stock on March 14, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations.
F4 Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026.
F5 Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 13,669 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold.
F6 Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025.